glpg3067
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 28, 2017 (NCT03128606)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- glpg3067
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05538585 | Phase 1 | Sep 27, 2022 | AbbVie |
| NCT05530278 | Phase 1 | Sep 20, 2022 | AbbVie |
| NCT04853368 | Phase 2 | Sep 13, 2021 | AbbVie |
| NCT03969888 | Phase 2 | Aug 27, 2019 | AbbVie |
| NCT03589313 | Phase 1 | Feb 12, 2018 | Galapagos NV |
| NCT03128606 | Phase 1 | Mar 28, 2017 | Galapagos NV |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 4 | 2 | 2019 |
| Galapagos NV | For profit | 2 | 2 | 1 | 2017 |
2 organizations
Page 1 / 1